secwatch.observer — SEC 8-K summary
======================================

Issuer:     Propanc Biopharma, Inc. (PPCB)
CIK:        0001517681
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001493152-26-008196
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Propanc Biopharma board changes: Kenyon retires, Brandt appointed
-----------------------------------------------------------------

- Dr. Julian Kenyon retired from Board on Feb 20, 2026; remains as medical advisor.
- Dr. Ralf Brandt appointed to Board same day; 30+ yrs pharma/oncology experience.
- Brandt to receive $45,000 annual compensation under Director Agreement.
- Brandt has served as CEO of vivoPharm and held exec roles at Novartis and Bionomics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517681/000149315226008196/0001493152-26-008196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517681/000149315226008196/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-008196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer